Spotlight Therapeutics nabs $30M to advance nonviral CRISPR gene therapies

By The Science Advisory Board staff writers

November 30, 2020 -- Spotlight Therapeutics has closed $30 million in series A financing to advance its nonviral gene editing therapeutics for in vivo editing.

Spotlight's proprietary targeted active gene editor (TAGE) technology platform develops programmable CRISPR ribonucleoproteins optimized for in vivo cell-targeted delivery. The company's approach avoids complexities and toxicities associated with cell, viral, and nanoparticle-based delivery methods. Lead candidates include those targeting hemoglobinopathies and immune-oncology applications.

The series A financing was led by GV, formerly Google Ventures.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.